WO2025253347 - TOPICAL DELIVERY OF MELANOCORTIN-1 RECEPTOR AGONISTS FORMULATIONS
National phase entry is expected:
Publication Number
WO/2025/253347
Publication Date
11.12.2025
International Application No.
PCT/IB2025/055844
International Filing Date
06.06.2025
Title **
[English]
TOPICAL DELIVERY OF MELANOCORTIN-1 RECEPTOR AGONISTS FORMULATIONS
[French]
ADMINISTRATION TOPIQUE DE FORMULATIONS D'AGONISTES DU RÉCEPTEUR DE LA MÉLANOCORTINE-1
Applicants **
VIMELA THERAPEUTICS, INC.
Inventors
BOUIX-PETER, Claire
DEAN, Yann
PRAUSNITZ, Mark
BERNSTEIN, James
LEMING, Robert
TADROS, Andrew
HARRIS, John
DE SMEDT, Thibaut
Priority Data
63/657,251
07.06.2024
US
63/760,961
20.02.2025
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4556 | |
| EPO | Filing, Examination, Granting | 61791 | |
| Japan | Filing, Examination, Granting | 4050 | |
| South Korea | Filing, Examination, Granting | 5872 | |
| USA | Filing, Examination, Granting | 16390 |
Total:
92,659
Contact Us
Abstract[English]
The disclosure relates to pharmaceutical compositions comprising a melanocortin-1 receptor (MC1R) agonist; a plurality of micrometer or millimeter scale particles; and a pharmaceutically acceptable carrier, and use thereof for the treatment of disease.[French]
La divulgation concerne des compositions pharmaceutiques comprenant un agoniste du récepteur de la mélanocortine-1 (MC1R) ; une pluralité de particules micrométriques ou millimétriques ; et un excipient pharmaceutiquement acceptable, et leur utilisation pour le traitement d'une maladie.